Who Supplies Dapagliflozin to India from SOUTH AFRICA

To import finished pharmaceutical formulations containing Dapagliflozin into India, manufacturers must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The registration process involves submitting Form 40/41, along with a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The Import License is valid for three years and is required for each consignment. The registration process typically takes several months, depending on the completeness of the application and the need for inspections.

Imported Dapagliflozin formulations must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, is essential to demonstrate the product's shelf-life in India's climate. Port inspections by customs drug inspectors ensure adherence to these standards before clearance.

In April 2025, the CDSCO mandated that all imported drugs, including finished formulations, must have an Import Registration Certificate and Import License. This regulation aims to prevent the sale of unapproved or illegal medicines in the Indian market. The policy also stipulates that banned drugs manufactured in Special Economic Zones (SEZ) are not permitted for transfer to the Domestic Tariff Area (DTA) for sale and distribution.

India imports finished Dapagliflozin formulations to meet the demand for patented and branded products not yet manufactured domestically. Specific dosage forms, such as extended-release tablets, are often sourced from international markets. The market size for Dapagliflozin in India is substantial, with a growing patient population requiring treatment for type 2 diabetes.

The Basic Customs Duty (BCD) for HS Code 30049099 is 10%. An additional Social Welfare Surcharge (SWS) of 10% is applied, resulting in a total duty of 20%. The Integrated Goods and Services Tax (IGST) is 12%, leading to a total landed duty of approximately 32.4%. There are no exemptions or concessional rates for imports from South Africa.

India sources Dapagliflozin formulations from South Africa due to the availability of patented formulations and specialized dosage forms not yet produced domestically. South African manufacturers offer high-quality products that meet international standards, providing a competitive advantage in the Indian market. Other suppliers include China, Germany, and the United States, but South Africa's unique formulations and quality standards make it a preferred choice.

India imports Dapagliflozin formulations from South Africa due to the availability of patented products and specialized dosage forms not yet manufactured domestically. South African manufacturers offer high-quality products that meet international standards, providing a competitive advantage in the Indian market.

Compared to other origins like China, the European Union, and the United States, South Africa offers competitive pricing and high-quality products. While China may offer lower prices, concerns about quality and regulatory compliance make South Africa a more reliable source. The European Union and the United States provide high-quality products but at higher prices, making South Africa a cost-effective alternative.

Potential risks include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. There have been no significant shortages reported in the past year.

1. 1Dual-Sourcing: Engage multiple suppliers to mitigate single-source risk.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC) to manage financial risk.
4. 4Supplier Qualification: Conduct thorough due diligence to ensure compliance with regulatory standards.
5. 5Regulatory Monitoring: Stay updated on changes in import policies and regulations affecting pharmaceutical imports.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Form 40/41: Submit the application for registration of the manufacturing premises and drug.
3. 3Drug Import License: Apply for an Import License from CDSCO.
4. 4No Objection Certificate (NOC): Obtain NOC from the Ministry of Health and Family Welfare, if required.
5. 5Customs Broker: Engage a licensed customs broker for clearance procedures.
6. 6Advance Ruling: Seek an advance ruling for HS Code 30049099 to confirm duty rates and classification.

1. 1Certificate of Analysis (CoA): Confirming compliance with Indian Pharmacopoeia standards.
2. 2Certificate of Pharmaceutical Product (CoPP): Issued by the regulatory authority in South Africa.
3. 3Good Manufacturing Practice (GMP) Certificate: Demonstrating adherence to international manufacturing standards.
4. 4Drug Master File (DMF): Providing detailed information about the drug substance.
5. 5Stability Data: For ICH Zone IV conditions, demonstrating product shelf-life.
6. 6Free Sale Certificate: Indicating that the product is freely sold in the country of origin.
7. 7Manufacturer Authorization: Authorizing the Indian importer to distribute the product.

Upon arrival, customs drug inspectors collect samples of each batch for testing at CDSCO-approved laboratories. Mandatory batch testing ensures compliance with Indian Pharmacop